SCHEMBL257301

SCHEMBL257301

CC1OC(=O)C(O)=C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092141 1.00 — —
SCHEMBL9423146 1.00 — —
SCHEMBL29581947 0.97 MAPT (0.41) —
SCHEMBL8749939 0.77 — —
SCHEMBL15437684 0.77 — —
SCHEMBL29281154 0.75 — —
SCHEMBL29281155 0.75 — —
SCHEMBL14938106 0.73 PPARG (0.43) —
SCHEMBL382020 0.72 PTPN1 (0.36) —
SCHEMBL2659803 0.72 AKT1 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112544619-B Bactericidal composition 沈阳中化农药化工研发有限公司 2022-04-12 — — CN claimed
US-11789307-B2 Colorant filter, backlight unit, and liquid crystal display device FUJIFILM CORPORATION (JP) 2023-10-17 — — US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230144527-A1 STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAME RENOVION, INC. 2023-05-11 — — US disclosed
WO-2023076534-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2023076586-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
EP-3821249-B1 SPECIFIC BINDING CHEMILUMINESCENT ASSAY 3M INNOVATIVE PROPERTIES CO (US) 2022-06-29 — — EP disclosed
EP-3393990-B1 PEG-BINDER ROCKWOOL INT (DK) 2022-06-08 — — EP disclosed
US-11320424-B2 Specific binding chemiluminescent assay 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-05-03 — — US disclosed
CN-112544619-B Bactericidal composition 沈阳中化农药化工研发有限公司 2022-04-12 — — CN disclosed
WO-2007071966-A1 PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2007-06-28 — — WO disclosed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 — — EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 — — US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 — — US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 — — EP disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 — — WO disclosed
EP-0938482-A1 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR Oxis International, Inc. (US) 1999-09-01 — — EP disclosed
WO-1998007714-A1 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR OXIS INTERNATIONAL, INC. (US) 1998-02-26 — — WO disclosed
US-5298526-A Optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids and pharmaceutical use THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1994-03-29 — — US disclosed
US-5095126-A Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1992-03-10 — — US disclosed
Send feedback